Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome

doi:10.1159/000450617

Review

. 2017 Jan;2(3-4):120-129.

doi: 10.1159/000450617. Epub 2016 Sep 23.

Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome

Raymond Fertig¹, Jerry Shapiro², Wilma Bergfeld³, Antonella Tosti¹

Affiliations

¹ Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Fla, USA.
² The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, N.Y., USA.
³ Departments of Dermatopathology Fellowship, Cleveland Clinic, Cleveland, Ohio, USA; Departments of Pathology, Dermatopathology Fellowship, Cleveland Clinic, Cleveland, Ohio, USA.

PMID: 28232919
PMCID: PMC5264352
DOI: 10.1159/000450617

Review

Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome

Raymond Fertig et al. Skin Appendage Disord. 2017 Jan.

. 2017 Jan;2(3-4):120-129.

doi: 10.1159/000450617. Epub 2016 Sep 23.

Authors

Raymond Fertig¹, Jerry Shapiro², Wilma Bergfeld³, Antonella Tosti¹

Affiliations

¹ Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Fla, USA.
² The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, N.Y., USA.
³ Departments of Dermatopathology Fellowship, Cleveland Clinic, Cleveland, Ohio, USA; Departments of Pathology, Dermatopathology Fellowship, Cleveland Clinic, Cleveland, Ohio, USA.

PMID: 28232919
PMCID: PMC5264352
DOI: 10.1159/000450617

Abstract

Postfinasteride syndrome (PFS) is a term recently coined to characterize a constellation of reported undesirable side effects described in postmarketing reports and small uncontrolled studies that developed during or after stopping finasteride treatment, and persisted after drug discontinuation. Symptoms included decreased libido, erectile dysfunction, sexual anhedonia, decreased sperm count, gynecomastia, skin changes, cognitive impairment, fatigue, anxiety, depression, and suicidal ideation. The aim of this study is to review the existing medical literature for evidence-based research of permanent sexual dysfunction and mood changes during treatment with 5-alpha-reductase inhibitors including finasteride and dutasteride.

Keywords: Dutasteride; Finasteride; Permanent sexual dysfunction; Physical adverse effects; Psyche; Psychiatric adverse effects; Side effects.

PubMed Disclaimer

Cited by

Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients.
Li X, Guo Y, Lu Y, Li H, Yan S, Li H, Li Y. Li X, et al. Transl Androl Urol. 2022 Oct;11(10):1452-1457. doi: 10.21037/tau-22-92. Transl Androl Urol. 2022. PMID: 36386264 Free PMC article.
Pumpkin Seed Oil-Loaded Niosomes for Topical Application: 5α-Reductase Inhibitory, Anti-Inflammatory, and In Vivo Anti-Hair Loss Effects.
Teeranachaideekul V, Parichatikanond W, Junyaprasert VB, Morakul B. Teeranachaideekul V, et al. Pharmaceuticals (Basel). 2022 Jul 27;15(8):930. doi: 10.3390/ph15080930. Pharmaceuticals (Basel). 2022. PMID: 36015077 Free PMC article.
Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review.
Pietrauszka K, Bergler-Czop B. Pietrauszka K, et al. Postepy Dermatol Alergol. 2022 Jun;39(3):472-478. doi: 10.5114/ada.2020.99947. Epub 2020 Oct 16. Postepy Dermatol Alergol. 2022. PMID: 35950120 Free PMC article. Review.
How to Deal with the Issues of Fertility, Malignancies, and the Postfinasteride Syndrome while Prescribing Finasteride for Male Pattern Hair Loss.
Trüeb RM, Luu NC, Gavazzoni Dias MFR, Dutra Rezende H. Trüeb RM, et al. Skin Appendage Disord. 2022 May;8(3):245-248. doi: 10.1159/000520493. Epub 2022 Jan 10. Skin Appendage Disord. 2022. PMID: 35707289 Free PMC article.
Psychiatric Comorbidity Related to the Therapy of Male Androgenetic Alopecia Independent of the 5-Alpha Reductase Pathway.
Trüeb RM. Trüeb RM. Skin Appendage Disord. 2022 Mar;8(2):169-170. doi: 10.1159/000518750. Epub 2021 Oct 21. Skin Appendage Disord. 2022. PMID: 35419416 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol. 1996;78:379–384. - PubMed
1. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology. 1995;46:631–637. - PubMed
1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224. - PubMed
1. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61:579–582. - PubMed
1. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999;54:670–678. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol. 1996;78:379–384. - PubMed

[2] Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol. 1996;78:379–384. - PubMed

[3] Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology. 1995;46:631–637. - PubMed

[4] Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology. 1995;46:631–637. - PubMed

[5] Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224. - PubMed

[6] Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224. - PubMed

[7] Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61:579–582. - PubMed

[8] Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61:579–582. - PubMed

[9] Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999;54:670–678. - PubMed

[10] Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999;54:670–678. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome

Affiliations

Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources